Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee
NCT ID: NCT06021444
Last Updated: 2023-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
250 participants
INTERVENTIONAL
2020-12-30
2023-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee
NCT02554240
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
NCT04886258
Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis.
NCT06779071
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
NCT00120900
Assessment of Protective Effect of JOINS on Cartilage in Knee Osteoarthritis
NCT01293955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
2. Un-blind: Investigator(or CRC).
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DKM420
Injecting to one side knee.
DKM420
A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Conjuran
Injecting to one side knee.
Conjuran
A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DKM420
A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Conjuran
A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed as osteoarthritis of Knee and satisfies the 3 of 6 ACR(American College of Rheumatology) conditions.
* Kellgren Lawrence grade (Ⅰ\~Ⅲ) at Visit 1 or within 24 weeks.
* 100mm VAS(Visual Analogue Scale) over 40mm.
* Etc.
Exclusion Criteria
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dongkook Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
chung-Ang University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DKM-420-MD-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.